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Introduction
Lung transplantation (LTx) is an established treatment 
option for end-stage lung diseases. Donor shortage is 
still a problem and particularly threatens the small-sized 
and urgent candidates awaiting an appropriate organ 
donor. Some transplant centers developed an advanced 
operative technique called “downsizing” or “size 
reduced” LTx.1–7) This includes peripheral wedge resec-
tions and lobar and split lung transplants to overcome 
size mismatch. Lobar LTx has been proposed to be an 
important surgical technique for those with smaller chest 
Background: Cadaveric lobar lung transplantation (L-LTx) is developed to overcome 
donor–recipient size mismatch. Controversial short- and long-term outcomes following 
L-LTx have been reported compared to full-sized lung transplantation (F-LTx). This 
study reports long-term outcomes after L-LTx.
Methods: We reviewed patients undergoing lung transplantation (LTx) between 2000 and 
2016. The decision to perform L-LTx was made based mainly on donor–recipient height 
discrepancy and visual assessment of donor lungs. Predicted donor–recipient total lung 
capacity (TLC) ratio was calculated more recently. Primary outcome was overall survival.
Results: In all, 370 bilateral LTx were performed during the study period, among those 
250 (67%) underwent F-LTx and 120 (32%) underwent L-LTx, respectively. One- and 
5-year survival rates were 85% vs. 90% and 53% vs. 63% for L-LTx and F-LTx, respec-
tively (p = 0.16). Chronic lung allograft dysfunction (CLAD)-free survival at 5 years was 
48% in L-LTx vs. 51% in F-LTx recipients (p = 0.89), respectively. Age, intraoperative 
extracorporeal membrane oxygenation (ECMO) use, intensive care unit (ICU) stay, and 
postoperative renal replacement therapy (RRT) were significant prognostic factors for 
survival using multivariate analysis.
Conclusions: Overall survival and CLAD-free survival following L-LTx were comparable to 
F-LTx. Given the ongoing donor organ shortage, cadaveric L-LTx remains as an important 
resource in LTx.
Keywords:  lobar lung transplantation, lung transplantation, survival, chronic rejection
1Department of Thoracic Surgery, Zurich University Hospital, 
University of Zurich, Zurich, Switzerland
2Division of Pulmonology, Zurich University Hospital, University 
of Zurich, Zurich, Switzerland
Received: July 28, 2020; Accepted: October 13, 2020
Corresponding author: Ilhan Inci, MD, FEBTS. Department of 
Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, 
CH-8091 Zurich, Switzerland
Email: ilhan.inci@usz.ch
Ann Thorac Cardiovasc Surg Advance Published Date: January 20, 2021
 doi: 10.5761/atcs.oa.20-00237
 1
Inci I, et al.
cavities and restrictive lung disease, leading to poten-
tially fewer cases of waiting-list mortality.4) Due to its 
technical challenges, lobar lung transplantation (L-LTx) 
is not widely performed.8)
Although publications reporting on survival after 
L-LTx exist, there is no published data with special focus 
on the incidence of CLAD in L-LTx. Chronic lung 
allograft dysfunction (CLAD) is the major obstacle for 
long-term survival in LTx.9–15) CLAD is reported to be 
the most common cause of death in recipients between 1 
and 5 years after LTx.10–15)
The aim of this study is to investigate the long-term 
outcomes after L-LTx compared to full-sized lung trans-
plantation (F-LTx).
Materials and Methods
Patient data are prospectively collected in our lung 
transplant program database starting from the first LTx 
conducted in November 1992. Between November 1992 
and the end of September 2016, 485 patients underwent 
LTx at our center. Unilateral LTx, re-transplantations, 
and LTx performed before the year 2000 were excluded. 
After those exclusions, 370 patients remained for analy-
sis and were included in the study. There were two groups, 
patients undergoing F-LTx (N = 250) and patients under-
going L-LTx (N = 120). The censor date for survival 
analysis was May 27, 2020. The decision to perform 
L-LTx was made prior to implantation based on donor–
recipient height discrepancy and visual assessment of 
donor. We also calculated donor–recipient predicted 
total lung capacity (TLC) ratio (D-R pTLC). TLC is cal-
culated according to standardized formula.16) Donor 
lobectomies were performed on the back table prior to 
implantation. Primary graft dysfunction (PGD) grading 
is performed according to International Society for Heart 
and Lung Transplantation (ISHLT) consensus state-
ment.17) CLAD was defined as a persistent, obstructive 
decrease in forced expiratory volume in 1 second (FEV1) 
with at least 20% compared to the mean of the two best 
post-transplant values, in the absence of other identifi-
able causes.15) Primary outcome was overall survival. 
Local research ethics committee approved the study 
(KEK Nr. 2019-00873).
Statistical Analysis
IBM SPSS version 25 (SPSS IBM, Armonk, New 
York, USA) was used for statistical analysis. Data are 
presented as median and interquartile range (IQR, 
25%–75%). Categorical variables were compared using 
chi-square tests. Mann–Whitney test was used to com-
pare continuous variables. Results of the multivariable 
linear or logistic regression analysis were adjusted for 
potential confounders such as recipient age, renal 
replacement therapy (RRT), and intraoperative extracor-
poreal membrane oxygenation (ECMO) use. Indepen-
dent risk factors were identified by a step-wise backward 
regression analysis. Kaplan–Meier Method (log rank 
test) was used to calculate unadjusted survival rate and 
CLAD-free survival. A p value less than 0.05 was con-
sidered as the threshold for statistical significance.
Results
In this series, L-LTx constituted 32% (120/370) of all 
LTx performed in this study cohort. Table 1 shows the 
recipient and donor characteristics of the study cohort. 
Gender and underlying diagnosis were statistically dif-
ferent between the two groups. D-R pTLC and donor 
and recipient height difference was also significantly dif-
ferent between the two groups.
There was a very significant correlation between D-R 
pTLC ratio and donor-recipient height difference (r = 
0.873, p = 0.000, Pearson correlation test).
Perioperative data are given in Table 2. L-LTx group 
needed more intraoperative ECMO use. Operation time 
and intensive care unit (ICU) stay were longer in the 
L-LTx group. In addition, L-LTx required more RRT, and 
the overall postoperative complication rate was higher. 
PGD Grade 2 and 3 at T48 was significantly higher in 
L-LTx recipients compared to F-LTx recipients.
In our series, 19 left upper lobe and 40 left lower lobe 
implantations were performed. On the right side, 25 
middle and right lower lobe, 112 right upper lobe and 
right lower lobe and 11 right upper lobe and middle lobe 
implantations were performed.
We observed higher rates of tracheotomy, complica-
tions related to ECMO and critical illness neuromyopa-
thy in L-LTx recipients (Table 3).
The rate of urgent listed recipients was 11.6% (N = 14) 
in L-LTx and 7.2% (N = 18) in F-LTx groups.
Early bronchial anastomosis complication occurred in 
one patient in the L-LTx group. Cartilage inversion in the 
anastomosis on the left side was corrected surgically 
after 24 hours following transplantation. As a late com-
plication in three cases in the L-LTx group, bronchial 
stump insufficiencies (back table lower lobectomy, bron-
chial closure with stapler) leading to empyema were 
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treated surgically using either omentum or muscle flap 
interposition. In the F-LTx group, we observed bronchial 
anastomosis complications in three cases, all of which 
were treated surgically early in the postoperative period.
Multivariate analysis of risk factors for mortality 
demonstrated that recipient age, intraoperative ECMO 
use, ICU stay, and RRT were risk factors for mortality in 
all patients (Table 4). Surgical procedure itself was not a 
risk factor.
30-d (96% vs. 97%) and 90-d survival rates (89% vs. 
94%) were comparable between the groups (L-LTx vs. 
F-LTx).
One- and 5-year survival rates were 85% vs. 90% and 
53% vs. 63% for L-LTx and F-LTx, respectively (p = 
0.16) (Fig. 1).
Median time to CLAD was 1096.5 days (IQR, 319, 
2432) for L-LTx and 1290 days (IQR, 531, 2444) for 
F-LTx groups. CLAD-free survival at 5 years was 48% 
in L-LTx and 51% in F-LTx recipients (p = 0.89). During 
the study period, CLAD Stage 3 occurred in 54 recipi-
ents in L-LTx and in 110 in F-LTx recipients (p = 0.2).
Discussion
L-LTx is an additional option utilized in limited number 
of centers to overcome organ shortage, particularly in 
small recipients and urgent cases.1–8) The gap between suit-
able donor lungs and the number of patients on the waiting 
list urged transplant centers to search for alternative strate-
gies such as use of extended criteria donors organs, 
Table 1 Recipient and donor characteristics
L-LTx (N = 120) F-LTx (N = 250) p Value
Age (years) 53 (43,58) 58 (50,60) 0.1
Sex (F/M) 71/49 101/149 0.001
Waiting list time (d) 190 (22,301) 328 (143,626) 0.1
CRP at LTx 12 (6,29) 3 (2,6) 0.2
Diagnosis 0.001
 CF 46 (38.3) 81 (32.4)
 COPD 21 (17.5) 89 (35.6)
 IPF 38 (31.6) 37 (14.8)
 PAH 5 (4.1) 15 (6)
 OTH 10 (8.3) 28 (11.2)
CMV (D/R) neg/pos 30 (25) 57 (22.8) 0.3
BMI (kg/m2) 20.5 (18.3,29.4) 23 (20.5,26.8) 0.3
R-Height (cm) 165 (159,172) 173 (168,182) 0.001
R-Weight (kg) 56 (51,85) 71 (58,86) 0.01
FEV1 preop (L) 0.8 (0.6,1.36) 0.85 (0.68,2.29) 0.6
FEV1 preop (%) 30 (25,44) 30 (20,65) 0.1
Donor characteristics
 Sex (F/M) 24/96 116/134 0.001
 Age (years) 54 (45,58) 53 (45,71) 0.6
 Height (cm) 180 (175,185) 172 (170,178) 0.001
 Weight (kg) 80 (70,85) 70 (60,80) 0.001
PaO2-FiO2 ratio (kPa) 47.1 (36.8,62.6) 44.7 (34.7,58.8) 0.3
D-R height difference (cm) 11.5 (6,19) 2 (-3,7) 0.001
D-R pTLC 1.24 (1.09,1.47) 1.02 (0.93,1.09) 0.001
Donor type 0.6
 DBD 115 236
 DCD 5 14
All values are presented as N (%) or median (Interquartile range: 25%–75%). BMI: body mass in-
dex; CF: cystic fibrosis; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary disease; 
CRP: C-reactive protein; d: days; D: donor; DBD: donation after brain death; DCD: donation 
after circulatory death; D-R pTLC: donor (D)-recipient (R) predicted total lung capacity (TLC) 
ratio; F: female; FEV1: forced expiratory volume in 1 second; FiO2: fraction of inspired oxygen; 
F-LTx: full sized lung transplantation; IPF: idiopathic pulmonary fibrosis; kPa: kilopascal; L: 
liter; L-LTx: lobar lung transplantation; M: male; OTH: other; PAH: pulmonary arterial hyperten-
sion; PaO2: arterial oxygen partial pressure; R: recipient
Ann Thorac Cardiovasc Surg Advance Published Date: January 20, 2021
 3
Inci I, et al.
Table 2 Perioperative characteristics and outcome of the recipients
L-LTx F-LTx p-value
Intraoperative ECMO 76 (63) 108 (43) 0.001
Bridge to LTx 0.3
 ECMO 11 (9.1) 14 (5.6)
 Intubated 1 (0.8) 2 (0.8)
 Tracheotomy 1 (0.8) –
 ILA 2 (1.6) 2 (0.8)
PreTx-Postop ECMO 7 (5.8) 5 (2)
Intra-Postop ECMO 9 (7.5) 6 (2.4)
Postop ECMO – 6 (2.4)
Total Op time (min) 420 (390,470) 415 (380,474) 0.006
Intubation Time (d) 1 (1,15) 1 (1,1) 0.08
ICU time (d) 12 (3,31) 2 (1,3) 0.01
RRT 19 (16) 21 (8) 0.04
PGD
 PGD2 T24 9 (13) 16 (13) 0.09
 PGD2 T48 5 (7) 14 (11) 0.04
 PGD2 T72 3 (4) 10 (8) 0.07
 PGD3 T24 15 (22) 12 (10) 0.09
 PGD3 T48 17 (25) 12 (10) 0.04
 PGD3 T72 16 (23) 12 (10) 0.07
Surgical complication 59 (49) 95 (38) 0.04
Re-exploration for bleeding 16 18 0.1
30-d mortality 6 (5) 10 (4) 0.7
90-d mortality 13 (11) 17 (7) 0.7
CLAD free survival (d) 1096.5 (319,2432) 1290 (531,2444) 0.89
All values are presented as N (%) or median (interquartile range: 25%–75%). CLAD: chronic lung 
allograft dysfunction; d: days; ECMO: extracorporeal membrane oxygenation; F-LTx: full-sized lung 
transplantation; ICU: intensive care unit; ILA: interventional lung assist device; L-LTx: lobar lung trans-
plantation; Op: operation; PGD: primary graft dysfunction; Pre-Tx: pretransplantation; Postop: postoper-
ative; RRT: renal replacement therapy
Table 3 Detailed list of complications occurred in the study groups
L-LTx F-LTx p Value
Tracheotomy 41 (34) 51 (20.4) 0.01
Thoracic Hernia 2 (1.6) 8 (3.2) 0.5
Lymphocele 9 (7.5) 13 (5.2) 0.3
Phrenic nerve injury 1 (0.8) 4 (1.6) 0.4
Hemothorax 24 (20) 24 (9.6) 0.1
Pleural effusion 6 (5) 21 (8.4) 0.1
Pneumothorax 4 (3.3) 12 (4.8) 0.1










Abdominal complications 8 (6.6) 26 (10.4) 0.5
Critical illness neuromyopathy 12 (10) 9 (3.6) 0.02
ECMO complications 13 (10.8) 8 (3.2) 0.01
All values are presented as N (%). *Bronchus anastomotic complication that occurred after discharge of the patient. 
ECMO: extra-corporeal membrane oxygenation; F-LTx: full sized lung transplantation; L-LTx: lobar lung trans-
plantation
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utilization of donation after circulatory death (DCD) 
donors, assessment and reconditioning of the so-called 
“marginal” lung in ex vivo lung perfusion system.18–21)
In our center, the rate of L-LTx consists one-third of 
our transplant population. Compared to series from 
Vienna, which reported 14% L-LTx, ours is approxi-
mately two times more than Vienna Group.2) One expla-
nation might be the 34% rate of CF recipients and when 
we add the fibrosis recipients, this ratio goes up to 70% 
of our total cohort. As expected, these patients are gener-
ally small or they have a restricted thorax cavity (fibrosis 
patients). In Switzerland, we have patient-based alloca-
tion (Swiss Organ Allocation System [SOAS]) since 
May 2007. Before May 2007, the allocation system was 
center based. In both of those systems, there are no lim-
itations for donor size during listing. In this system, we 
have “Urgent” status, which gives the recipient priority 
to get the first available donor lung, such as bridged to 
transplantation on ECMO and/or intubated patient. In 
our series, urgent-listed patients in L-LTx group were 
higher than F-LTx group.
L-LTx as a technique is not new and has been first 
published by Bisson et al.22) in the early 1990s. Other 
than to adapt a large size graft for a small recipient, this 
method also gives the opportunity to resect a lobe due to 
an unexpected pathology, such as total consolidated 
lung.2)
L-LTx is a technically challenging procedure requir-
ing an experienced surgeon to perform a lobectomy on 
the back table.1,2)
Decision when to perform L-LTx differs among the 
centers. Donor–recipient difference or ratio in body 
weight and height,1,23,24) chest circumference and chest 
X-ray vertical and transverse dimensions,25) and the use 
of donor and recipient TLC for optimal size matching 
have been reported.2,26,27) Slama and co-workers from 
Vienna reported that a TLC size discrepancy of less than 
20% could be corrected by wedge resection alone, 
whereas a size reduction of 20%–60% requires L-LTX.2) 
However, final decision is made during the LTx proce-
dure.1,2) Although the international standard in most cen-
ters for donor–recipient size matching is based on D-R 
pTLC ratio,8) in our center we mainly use height differ-
ence between donor and recipient. We also calculate 
pTLC ratio for our databank prospectively. As we 
demonstrated a significant correlation between donor–
recipient height difference and D-R pTLC ratio, we 
believe that it is also possible and reliable to decide size 
mismatch with donor–recipient height difference.
ECMO use has been recommended to prevent reper-
fusion injury of the first-transplanted lobe.1–6) The utili-
zation rate of ECMO in published series varied between 
32% and 70%.2–5) Despite the use of intraoperative 
ECMO, the occurrence rate of PGD rate in published 
reports could be as high as 54%.2,4,5) We observed 23% 
PGD 3 at T72 in L-LTx group. As the etiology of PGD is 
multifactorial, it is difficult to speculate only with the 
type of surgery combined with intraoperative ECMO use 
for high incidence of PGD in those series. In our series, 
we used ECMO in 63%. A higher intraoperative ECMO 
use rate might be expected, but when the first side is full-
sized transplantation and only the second side an L-LTx, 
Table 4 Multivariate analysis of risk factors for mortality
Variable Relative risk 95% CI p Value
Recipient age  1.022 1.013–1.032  0.001
Intraoperative ECMO use 1.34 1.010–1.777 0.04
ICU stay 1.01 1.004–1.016  0.003
RRT 1.66 1.052–2.620 0.03
ECMO: extra-corporeal membrane oxygenation; ICU: intensive care unit; RRT: renal replace-
ment therapy
Fig. 1  Kaplan–Meier survival curve showing the overall survival 
between F-LTx and L-LTx. One- and 5-year survival rates 
were comparable between the two study groups (p = 
0.16). F-LTx: full-sized lung transplantation; L-LTx: 
lobar lung transplantation 
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the ECMO might be omitted. For bilateral L-LTx, ECMO 
implementation is recommended at the beginning of the 
transplantation.2) In addition, routine practice of implant-
ing the second lobe on ECMO to avoid over perfusion of 
the first implanted lobe has been reported.6)
Technical complications, such as bronchial anasto-
motic problems, kinking of vascular anastomoses, and 
remaining pleural dead space might occur.1,2) The rate of 
bronchial anastomotic complications was 5.5% and 
13%, respectively, in the two recent series reporting 
L-LTx.3,23) Early anastomotic problems occurred only in 
one patient in our L-LTx Group, which was corrected 
surgically 24 hours following the transplantation. The 
other three cases had bronchus stump insufficiency lead-
ing to empyema, all of which occurred late and after dis-
charge of the recipients from the hospital. All of these 
cases were treated surgically by decortication and cover-
ing the stump with either omentum or thoracic muscle. 
Although all lobar combinations can be used in L-LTx, it 
is extremely important not to leave a bronchus stump by 
resecting the right lower lobe for implantation of the 
upper and middle lobes.2,4) On the left side, we also rec-
ommend not to leave a bronchus stump with stapler to 
make the anastomosis main-to-main bronchus: Lobar 
bronchus should be implanted to the recipient main 
bronchus.
Overall survival rates from different centers showed 
comparable results comparing L-LTx and F-LTx groups.4,5) 
However, the Vienna Group, in their recent publication 
including 138 recipients, reported inferior survival in the 
L-LTx group compared to the F-LTx group.2) We observed 
comparable survival between L-LTx and F-LTx groups as 
also reported from other centers.4,6)
CLAD is reported to be the most common cause of 
death in recipients between 1 and 5 years after LTx.9) 
CLAD has an obstructive phenotype known as bronchiol-
itis obliterans syndrome (BOS).10,11) PGD is one of the 
risk factors for the development of CLAD.15) Increased 
rate of PGD has been reported from some centers after 
L-LTx2,4,5) that may contribute to the development of 
CLAD.15) We observed a higher PGD Grade 2 and 3 at 
T48 in L-LTx recipients compared to F-LTx recipients. 
Despite high PGD grade observed in L-LTx group, 
CLAD-free survival was comparable between the two 
groups.
One of the limitations of our study is that we did not 
have the phenotypes of CLAD for the groups. The other 
limitation might be that we did not calculate the D-R 
pTLC ratio routinely at the beginning of the study.
In conclusion, in our series, overall and CLAD-free 
survival following L-LTx was comparable to F-LTx. 
Given the ongoing donor organ shortage, cadaveric 
L-LTx in our hands remains a viable option, in particu-
lar, for small and urgently listed LTx candidates.
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